Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Autoimmune Disorders

  Free Subscription


Articles published in Ann Neurol

Retrieve available abstracts of 71 articles:
HTML format
Text format



Single Articles


    August 2018
  1. SEBASTIAN LOPEZ-CHIRIBOGA A, Klein C, Zekeridou A, McKeon A, et al
    LGI1 and CASPR2 Neurological Autoimmunity in Children.
    Ann Neurol. 2018 Aug 3. doi: 10.1002/ana.25310.
    PubMed     Text format     Abstract available


    July 2018
  2. FUJII T, Yamasaki R, Iinuma K, Tsuchimoto D, et al
    A novel autoantibody against plexin D1 in patients with neuropathic pain.
    Ann Neurol. 2018 Jul 16. doi: 10.1002/ana.25279.
    PubMed     Text format     Abstract available


    June 2018
  3. JIA X, Madireddy L, Caillier S, Santaniello A, et al
    Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.
    Ann Neurol. 2018 Jun 16. doi: 10.1002/ana.25263.
    PubMed     Text format     Abstract available


    May 2018
  4. DISANTO G, Zecca C, MacLachlan S, Sacco R, et al
    Prodromal symptoms of multiple sclerosis in primary care.
    Ann Neurol. 2018 May 8. doi: 10.1002/ana.25247.
    PubMed     Text format     Abstract available


    April 2018
  5. TANKOU SK, Regev K, Healy BC, Tjon E, et al
    A probiotic modulates the microbiome and immunity in multiple sclerosis.
    Ann Neurol. 2018 Apr 20. doi: 10.1002/ana.25244.
    PubMed     Text format     Abstract available


  6. VOGRIG A, Brigo F, Valente M, Gigli GL, et al
    Epidemiology of autoimmune versus infectious encephalitis.
    Ann Neurol. 2018 Apr 10. doi: 10.1002/ana.25229.
    PubMed     Text format    


  7. DUBEY D, Pittock SJ, Toledano M, Flanagan EP, et al
    Reply to "Epidemiology of autoimmune versus infectious encephalitis".
    Ann Neurol. 2018 Apr 10. doi: 10.1002/ana.25230.
    PubMed     Text format    


    March 2018
  8. CRAMER SP, Simonsen HJ, Varatharaj A, Galea I, et al
    Permeability of the blood-brain barrier predicts no evidence of disease activity at two years after natalizumab or fingolimod treatment in relapsing-remitting multiple sclerosis.
    Ann Neurol. 2018 Mar 31. doi: 10.1002/ana.25219.
    PubMed     Text format     Abstract available


  9. ANTEL J
    The reality of "ghosts" in authorship of clinical trials in multiple sclerosis.
    Ann Neurol. 2018 Mar 13. doi: 10.1002/ana.25199.
    PubMed     Text format    


  10. COLES A
    Authorship of phase 3 trials in multiple sclerosis.
    Ann Neurol. 2018 Mar 8. doi: 10.1002/ana.25203.
    PubMed     Text format    


  11. MAGLIOZZI R, Howell OW, Nicholas R, Cruciani C, et al
    Inflammatory intrathecal profiles and cortical damage in multiple sclerosis.
    Ann Neurol. 2018 Mar 8. doi: 10.1002/ana.25197.
    PubMed     Text format     Abstract available


    January 2018
  12. ESHAGHI A, Prados F, Brownlee W, Altmann DR, et al
    Deep grey matter volume loss drives disability worsening in multiple sclerosis.
    Ann Neurol. 2018 Jan 13. doi: 10.1002/ana.25145.
    PubMed     Text format     Abstract available


  13. DUBEY D, Pittock SJ, Kelly CR, McKeon A, et al
    Autoimmune Encephalitis Epidemiology and a comparison to Infectious Encephalitis.
    Ann Neurol. 2018 Jan 2. doi: 10.1002/ana.25131.
    PubMed     Text format     Abstract available


    December 2017
  14. GILES DA, Washnock-Schmid JM, Duncker PC, Dahlawi S, et al
    Myeloid cell plasticity in the evolution of central nervous system autoimmunity.
    Ann Neurol. 2017 Dec 28. doi: 10.1002/ana.25128.
    PubMed     Text format     Abstract available


  15. GREENFIELD AL, Hauser SL
    B Cell Therapy for Multiple Sclerosis: Entering an Era.
    Ann Neurol. 2017 Dec 15. doi: 10.1002/ana.25119.
    PubMed     Text format     Abstract available


  16. PATTERSON KR, Dalmau J, Lancaster E
    Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia.
    Ann Neurol. 2017 Dec 15. doi: 10.1002/ana.25120.
    PubMed     Text format     Abstract available


    November 2017
  17. KANAI T, Uzawa A, Sato Y, Suzuki S, et al
    A clinical predictive score for postoperative myasthenic crisis.
    Ann Neurol. 2017;82:841-849.
    PubMed     Text format     Abstract available


    October 2017
  18. BARBOUR C, Kosa P, Komori M, Tanigawa M, et al
    Molecular-based diagnosis of Multiple Sclerosis and its progressive stage.
    Ann Neurol. 2017 Oct 23. doi: 10.1002/ana.25083.
    PubMed     Text format     Abstract available


  19. AZODI S, Nair G, Enose-Akahata Y, Charlip E, et al
    Imaging Spinal Cord Atrophy in Progressive Myelopathies: HTLV-I Associated Neurologic Disease (HAM/TSP) and Multiple Sclerosis (MS).
    Ann Neurol. 2017 Oct 10. doi: 10.1002/ana.25072.
    PubMed     Text format     Abstract available


  20. JENDE JME, Hauck GH, Diem R, Weiler M, et al
    Peripheral nerve involvement in multiple sclerosis Demonstration by magnetic resonance neurography.
    Ann Neurol. 2017 Oct 10. doi: 10.1002/ana.25068.
    PubMed     Text format     Abstract available


  21. MAINERO C, Louapre C
    Unravelling cortical pathology in multiple sclerosis using the T1-/T2-weighted ratio?
    Ann Neurol. 2017 Oct 4. doi: 10.1002/ana.25063.
    PubMed     Text format    


  22. WIJNANDS JMA, Tremlett H
    Concussion may not cause multiple sclerosis.
    Ann Neurol. 2017 Oct 4. doi: 10.1002/ana.25061.
    PubMed     Text format    


  23. MONTGOMERY S, Hiyoshi A, Burkill S, Alfredsson L, et al
    Reply to: Concussion may not cause multiple sclerosis.
    Ann Neurol. 2017 Oct 4. doi: 10.1002/ana.25062.
    PubMed     Text format    


    September 2017
  24. FITZGERALD KC, Munger KL, Ascherio A
    Reply to "Stratified analyses are necessary to verify the influence of salt intake in multiple sclerosis".
    Ann Neurol. 2017 Sep 29. doi: 10.1002/ana.25055.
    PubMed     Text format    


  25. ZAHEDNASAB H, Harirchian MH, Karampoor S, Keyvani H, et al
    MMP-9 as a biomarker of PML development in MS patients receiving Natalizumab.
    Ann Neurol. 2017 Sep 4. doi: 10.1002/ana.25037.
    PubMed     Text format    


  26. FISSOLO N, Pignolet B, Brassat D, Comabella M, et al
    Reply: MMP-9 as a biomarker of PML development in MS patients receiving Natalizumab.
    Ann Neurol. 2017 Sep 4. doi: 10.1002/ana.25039.
    PubMed     Text format    


  27. MONTGOMERY S, Hiyoshi A, Burkill S, Alfredsson L, et al
    Concussion in adolescence and risk of multiple sclerosis.
    Ann Neurol. 2017 Sep 4. doi: 10.1002/ana.25036.
    PubMed     Text format     Abstract available


    August 2017
  28. NAKAMURA K, Chen JT, Ontaneda D, Fox RJ, et al
    T1-/T2-weighted ratio differs in demyelinated cortex of multiple sclerosis.
    Ann Neurol. 2017 Aug 18. doi: 10.1002/ana.25019.
    PubMed     Text format     Abstract available


  29. RIGHART R, Biberacher V, Jonkman LE, Klaver R, et al
    Cortical pathology in MS detected by the T1/T2-weighted ratio from routine MRI.
    Ann Neurol. 2017 Aug 18. doi: 10.1002/ana.25020.
    PubMed     Text format     Abstract available


  30. DALAKAS MC, Rakocevic G, Dambrosia JM, Alexopoulos H, et al
    A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome.
    Ann Neurol. 2017;82:271-277.
    PubMed     Text format     Abstract available


    July 2017
  31. YATES RL, Esiri MM, Palace J, Jacobs B, et al
    Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex.
    Ann Neurol. 2017 Jul 18. doi: 10.1002/ana.24997.
    PubMed     Text format     Abstract available


  32. FISSOLO N, Pignolet B, Matute-Blanch C, Trivino JC, et al
    MMP9 is decreased in natalizumab-treated MS patients at risk for PML.
    Ann Neurol. 2017 Jul 6. doi: 10.1002/ana.24987.
    PubMed     Text format     Abstract available


    May 2017
  33. FITZGERALD KC, Munger KL, Hartung HP, Freedman MS, et al
    Sodium intake and multiple sclerosis activity and progression in BENEFIT.
    Ann Neurol. 2017 May 26. doi: 10.1002/ana.24965.
    PubMed     Text format     Abstract available


  34. DISANTO G, Barro C, Benkert P, Naegelin Y, et al
    Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
    Ann Neurol. 2017 May 16. doi: 10.1002/ana.24954.
    PubMed     Text format     Abstract available


  35. CUI QL, Khan D, Rone M, Rao V, et al
    Sublethal oligodendrocyte injury: A reversible condition in multiple sclerosis?
    Ann Neurol. 2017 May 3. doi: 10.1002/ana.24944.
    PubMed     Text format     Abstract available


  36. IAFFALDANO P, Simone M, Lucisano G, Ghezzi A, et al
    Prognostic indicators in pediatric clinically isolated syndrome.
    Ann Neurol. 2017;81:729-739.
    PubMed     Text format     Abstract available


    April 2017
  37. ANDRODIAS G, Bernard E, Biotti D, Collongues N, et al
    Multiple sclerosis broke my heart.
    Ann Neurol. 2017 Apr 24. doi: 10.1002/ana.24935.
    PubMed     Text format     Abstract available


  38. SELMAJ I, Cichalewska M, Namiecinska M, Galazka G, et al
    Global Exosome Transcriptome Profiling Reveals Biomarkers for Multiple Sclerosis.
    Ann Neurol. 2017 Apr 15. doi: 10.1002/ana.24931.
    PubMed     Text format     Abstract available


    March 2017
  39. TAWARA N, Yamashita S, Zhang X, Korogi M, et al
    Pathomechanisms of anti-cN1A autoantibodies in sporadic inclusion body myositis.
    Ann Neurol. 2017 Mar 20. doi: 10.1002/ana.24919.
    PubMed     Text format     Abstract available


  40. TREMLETT H, Bauer KC, Appel-Cresswell S, Finlay BB, et al
    The gut microbiome in human neurological disease: A review.
    Ann Neurol. 2017;81:369-382.
    PubMed     Text format     Abstract available


    February 2017
  41. AROUCHE-DELAPERCHE L, Allenbach Y, Amelin D, Preusse C, et al
    Pathogenic role of anti-SRP and anti-HMGCR antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies.
    Ann Neurol. 2017 Feb 22. doi: 10.1002/ana.24902.
    PubMed     Text format     Abstract available


  42. KIM TJ, Lee ST, Moon J, Sunwoo JS, et al
    Anti-LGI1 encephalitis is associated with unique HLA subtypes.
    Ann Neurol. 2017;81:183-192.
    PubMed     Text format     Abstract available


    January 2017
  43. GONZALEZ-BILLAULT C
    The identity of the PCA-2 autoantibody antigen is finally revealed.
    Ann Neurol. 2017 Jan 30. doi: 10.1002/ana.24884.
    PubMed     Text format    


  44. FLANAGAN EP, Hinson SR, Lennon VA, Fang B, et al
    GFAP-IgG as Biomarker of Autoimmune Astrocytopathy: Analysis of 102 Patients.
    Ann Neurol. 2017 Jan 24. doi: 10.1002/ana.24881.
    PubMed     Text format     Abstract available


    December 2016
  45. HERRANZ E, Hooker JM, Izquierdo-Garcia D, Loggia ML, et al
    11 C-PBR28 increase in multiple sclerosis reflects neuroinflammation.
    Ann Neurol. 2016 Dec 29. doi: 10.1002/ana.24865.
    PubMed     Text format    


  46. RAFFEL J, Sridharan S, Nicholas R
    [11 C]PBR-28 PET in multiple sclerosis: Neuroinflammation or otherwise?
    Ann Neurol. 2016 Dec 26. doi: 10.1002/ana.24853.
    PubMed     Text format    


    October 2016
  47. GOBEL K, Kraft P, Pankratz S, Gross CC, et al
    Prothrombin and factor X are elevated in multiple sclerosis patients.
    Ann Neurol. 2016 Oct 24. doi: 10.1002/ana.24807.
    PubMed     Text format     Abstract available


    September 2016
  48. HERRANZ E, Gianni C, Louapre C, Treaba CA, et al
    The neuroinflammatory component of gray matter pathology in multiple sclerosis.
    Ann Neurol. 2016 Sep 30. doi: 10.1002/ana.24791.
    PubMed     Text format     Abstract available


    August 2016
  49. CORTESE M, Riise T, Bjornevik K, Bhan A, et al
    Pre-clinical disease activity in multiple sclerosis- a prospective study on cognitive performance prior to first symptom.
    Ann Neurol. 2016 Aug 23. doi: 10.1002/ana.24769.
    PubMed     Text format     Abstract available


  50. MEYER SAUTEUR PM, Huizinga R, Tio-Gillen AP, Roodbol J, et al
    Mycoplasma pneumoniae triggering the Guillain-Barre syndrome: A case-control study.
    Ann Neurol. 2016 Aug 4. doi: 10.1002/ana.24755.
    PubMed     Text format     Abstract available


    July 2016
  51. CREE B, Gourraud PA, Oksenberg JR, Bevan C, et al
    Long-term evolution of multiple sclerosis disability in the treatment era.
    Ann Neurol. 2016 Jul 27. doi: 10.1002/ana.24747.
    PubMed     Text format     Abstract available


  52. WINDER K, Linker RA, Seifert F, Deutsch M, et al
    Neuroanatomic Correlates of Female Sexual Dysfunction in Multiple Sclerosis.
    Ann Neurol. 2016 Jul 27. doi: 10.1002/ana.24746.
    PubMed     Text format     Abstract available


  53. WHITE MK, Wollebo HS, Beckham JD, Tyler KL, et al
    Zika virus: An emergent neuropathological agent.
    Ann Neurol. 2016 Jul 27. doi: 10.1002/ana.24748.
    PubMed     Text format     Abstract available


    June 2016
  54. GERDES LA, Held K, Beltran E, Berking C, et al
    CTLA-4 as immunological checkpoint in the development of multiple sclerosis.
    Ann Neurol. 2016 Jun 28. doi: 10.1002/ana.24715.
    PubMed     Text format     Abstract available


    May 2016
  55. JOKUBAITIS VG, Spelman T, Kalincik T, Lorscheider J, et al
    Predictors of long-term disability accrual in relapse-onset multiple sclerosis.
    Ann Neurol. 2016 May 4. doi: 10.1002/ana.24682.
    PubMed     Text format     Abstract available


    April 2016
  56. HARSCHNITZ O, van den Berg LH, Johansen LE, Jansen MD, et al
    Autoantibody pathogenicity in a multifocal motor neuropathy iPSC-derived model.
    Ann Neurol. 2016 Apr 30. doi: 10.1002/ana.24680.
    PubMed     Text format     Abstract available


  57. BODINI B, Veronese M, Turkheimer F, Stankoff B, et al
    Benzothiazole and stilbene derivatives as promising PET myelin radiotracers for multiple sclerosis.
    Ann Neurol. 2016 Apr 21. doi: 10.1002/ana.24667.
    PubMed     Text format    


  58. MATIAS-GUIU JA, Cabrera-Martin MN, Oreja-Guevara C, Carreras JL, et al
    PiB and other amyloid-PET tracers for the study of white matter and multiple sclerosis.
    Ann Neurol. 2016 Apr 21. doi: 10.1002/ana.24666.
    PubMed     Text format    


  59. HOKARI M, Yokoseki A, Arakawa M, Saji E, et al
    Clinicopathological features in anterior visual pathway in neuromyelitis optica.
    Ann Neurol. 2016;79:605-24.
    PubMed     Text format     Abstract available


    March 2016
  60. ALPING P, Frisell T, Novakova L, Islam-Jakobsson P, et al
    Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
    Ann Neurol. 2016 Mar 31. doi: 10.1002/ana.24651.
    PubMed     Text format     Abstract available


  61. LASSMANN H
    Demyelination and Neurodegeneration in Multiple Sclerosis: The Role of Hypoxia.
    Ann Neurol. 2016 Mar 9. doi: 10.1002/ana.24632.
    PubMed     Text format    


  62. JELCIC I, Jelcic I, Kempf C, Largey F, et al
    Mechanisms of immune escape in central nervous system infection with neurotropic JC virus variant.
    Ann Neurol. 2016;79:404-18.
    PubMed     Text format     Abstract available


  63. FLANAGAN EP, Kaufmann TJ, Krecke KN, Aksamit AJ, et al
    Discriminating long myelitis of neuromyelitis optica from sarcoidosis.
    Ann Neurol. 2016;79:437-47.
    PubMed     Text format     Abstract available


    February 2016
  64. BODINI B, Veronese M, Garcia-Lorenzo D, Battaglini M, et al
    Dynamic imaging of individual remyelination profiles in multiple sclerosis.
    Ann Neurol. 2016 Feb 18. doi: 10.1002/ana.24620.
    PubMed     Text format     Abstract available


  65. FLANAGAN EP, Cabre P, Weinshenker BG, St Sauver J, et al
    Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum.
    Ann Neurol. 2016 Feb 17. doi: 10.1002/ana.24617.
    PubMed     Text format     Abstract available


  66. WEINSHENKER BG
    What Is the Optimal Sequence of Rescue Treatments for Attacks of Neuromyelitis Optica Spectrum Disorder?
    Ann Neurol. 2016;79:204-5.
    PubMed     Text format    


  67. KLEITER I, Gahlen A, Borisow N, Fischer K, et al
    Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses.
    Ann Neurol. 2016;79:206-16.
    PubMed     Text format     Abstract available


    January 2016
  68. DESAI RA, Davies AL, Tachrount M, Kasti M, et al
    Cause and prevention of demyelination in a model multiple sclerosis lesion.
    Ann Neurol. 2016 Jan 27. doi: 10.1002/ana.24607.
    PubMed     Text format     Abstract available


    November 2015
  69. KANTARCI OH, Lebrun C, Siva A, Keegan MB, et al
    Primary Progressive MS evolving from Radiologically Isolated Syndrome.
    Ann Neurol. 2015 Nov 24. doi: 10.1002/ana.24564.
    PubMed     Text format     Abstract available


  70. XIA Z, White CC, Owen EK, Von Korff A, et al
    GEMS Project: A Platform to Investigate Multiple Sclerosis Risk.
    Ann Neurol. 2015 Nov 19. doi: 10.1002/ana.24560.
    PubMed     Text format     Abstract available


  71. SAIDHA S, Al-Louzi O, Ratchford JN, Bhargava P, et al
    Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four-year study.
    Ann Neurol. 2015;78:801-13.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: